Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Briacell Therapeutics Corp (BCTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: BCTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $150
1 Year Target Price $150
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -73.45% | Avg. Invested days 16 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.32M USD | Price to earnings Ratio - | 1Y Target Price 150 |
Price to earnings Ratio - | 1Y Target Price 150 | ||
Volume (30-day avg) 2 | Beta 1.41 | 52 Weeks Range 6.00 - 214.50 | Updated Date 08/29/2025 |
52 Weeks Range 6.00 - 214.50 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -76.9 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -131.54% | Return on Equity (TTM) -688.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 860159 | Price to Sales(TTM) - |
Enterprise Value 860159 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.38 | Shares Outstanding 1755110 | Shares Floating 551398 |
Shares Outstanding 1755110 | Shares Floating 551398 | ||
Percent Insiders 2.55 | Percent Institutions 9.67 |
Upturn AI SWOT
Briacell Therapeutics Corp
Company Overview
History and Background
Briacell Therapeutics Corp is a clinical-stage biotechnology company. They are focused on the development of immunotherapies to fight cancer. Founded to create a new class of targeted immunotherapies.
Core Business Areas
- Immuno-Oncology Therapeutics: Development of novel immunotherapies using genetically engineered cell lines designed to activate the patient's immune system to fight cancer.
Leadership and Structure
The leadership team includes individuals with experience in oncology drug development and biotechnology management. The company operates with a focus on research and development.
Top Products and Market Share
Key Offerings
- Bria-IMTu2122: Bria-IMTu2122 is Briacell's lead investigational product candidate. It is an off-the-shelf personalized immunotherapy targeting advanced breast cancer. The market share data is still emerging as the therapy is under development. Competitors include large pharmaceutical companies with established breast cancer therapies (e.g., Pfizer, Roche, Novartis).
Market Dynamics
Industry Overview
The immuno-oncology industry is a rapidly growing sector focused on developing therapies that harness the body's immune system to fight cancer. The market is driven by increasing cancer prevalence and advancements in immunotherapy research.
Positioning
Briacell is positioned as a clinical-stage company focused on personalized immunotherapies. Their competitive advantage lies in their unique approach to activating the immune system and the potential for their therapies to address unmet needs in cancer treatment.
Total Addressable Market (TAM)
The global cancer immunotherapy market is expected to reach hundreds of billions of dollars. Briacell, while smaller, is positioned to capture a share of this market with successful development and commercialization of Bria-IMTu2122.
Upturn SWOT Analysis
Strengths
- Novel immunotherapy approach
- Personalized treatment potential
- Clinical-stage product candidate
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- High regulatory hurdles
- Smaller size compared to competitors
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer types
- Advancements in immunotherapy technology
Threats
- Competition from established therapies
- Clinical trial failures
- Regulatory delays
- Economic downturn affecting investment in biotechnology
Competitors and Market Share
Key Competitors
- PFE
- RHHBY
- NVS
Competitive Landscape
Briacell competes with larger pharmaceutical companies in the cancer immunotherapy market. Their advantage lies in their personalized approach, but they face challenges related to resources and market access.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advancement of Bria-IMTu2122 through clinical trials.
Future Projections: Future growth depends on successful clinical trial outcomes and potential commercialization or partnerships.
Recent Initiatives: Recent initiatives include ongoing clinical trials of Bria-IMTu2122 and exploration of new immunotherapy approaches.
Summary
Briacell Therapeutics is a high-risk, high-reward clinical-stage biotech company focused on developing innovative immunotherapies. Its success is heavily reliant on positive clinical trial outcomes and regulatory approvals. The company's personalized approach offers potential advantages, but financial constraints and competition from larger players pose significant challenges. Briacell needs to secure strategic partnerships to enhance its growth trajectory.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on independent research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Briacell Therapeutics Corp
Exchange NASDAQ | Headquaters West Vancouver, BC, Canada | ||
IPO Launch date 2021-02-24 | CEO, President & Director Dr. William V. Williams FCPA, M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://briacell.com |
Full time employees - | Website https://briacell.com | ||
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.